GLP-1 medication access and direct-to-consumer drug programs

Accessing GLP-1 medications, such as semaglutide and tirzepatide, in the United States typically requires a medical evaluation, a prescription, and an ongoing care plan through a licensed clinician. Patients may utilize in-person providers, such as primary care physicians or endocrinologists, or telehealth platforms to complete medical intakes involving BMI, medical history, and weight-loss goals.

While direct-to-consumer drug programs offer the potential for more affordable access to GLP-1s, experts note that purchasing medications outside of traditional insurance benefits may result in higher costs and increased long-term risks.